FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543464> ?p ?o ?g. }

• W4362543464 endingPage "2801" @default.
• W4362543464 startingPage "2801" @default.
• W4362543464 abstract "Abstract This feasibility study aimed to establish the logistically feasible protocol for the Phase I trial in Kenyan pediatric cancer patients. The trial’s ultimate goal is to rationally optimize the dosing of the anti-cancer drug, Vincristine (VCR). The CYP3A5 enzyme more efficiently metabolizes VCR to its M1 metabolite than the CYP3A4 enzyme as reported by Renbarger. CYP3A5 expression varies among Kenyans (90%), African Americans (AA, 70%), and Caucasians (10-20%). In order to dose the patients rationally among the different ethnicities, the pre-requisite is to comprehensively understand the pharmacokinetic (PK) disposition of VCR and M1, as well as the conversion kinetics from VCR to M1. Seventy-seven (77) Kenyan pediatric cancer patients (37M/40F, 1-16 yo, BSA of 0.38-1.64 m2) with 9 types of cancers, Acute Lymphoblastic Leukemia (ALL, N=28), and Non-Hodgkin’s Lymphoma (NHL, N=21), Hodgkin's Lymphoma (HL, N=5), Wilm’s Tumor (WT/NEPHRO, N=13), Retinoblastoma (RETINO, N=5), Rhabdomyosarcoma (RMS, N=2), Hepatoma (HEPATO, N=1), Teratoma (TERA, N=1), and Neuroblastoma (NEURO, N=1) were recruited. Dried blood spot (DBS) samples of the Kenyan pediatric patients after an IV dose of VCR (0.9-2.2 mg/m2) were collected via finger stick at various time points depending on the feasibility. Concentrations were quantified for VCR and M1 using a validated LC-MS/MS assay with LLOQ of 0.6 ng/ml for VCR and 0.4 ng/ml for M1. The PK co-models of VCR and M1 metabolite were developed, and PK parameters were derived for individual subjects. Using Phoenix NLME 8.0, model discrimination was performed by minimizing the Akaike Information Criteria (AIC) values and visual comparisons of the quality of fitness of the plots. The PK parameters were derived from the best fit PK model. Large interpatient variability was observed. The VCR to M1 conversion was active in 38-42% of subjects yielding higher M1 than VCR in plasma profiles. The conversion kinetics in k12 ranged from &lt; 0.01 to 44 hr-1. The mean k12 among WT, ALL, and NHL patients were 4.27+6.31, 5.83+13.00, and 1.98+3.31 hr-1, respectively. The elimination rate constants of VCR and M1 were characterized as 3.89+9.19 and 8.37+21.84 in the WT group, 1.75+4.44 and 17.75+26.37 in the ALL group, and 2.17+7.68 and 19.41+31.45 in the NHL group. The covariate analyses with age, sex, and type of cancer did not further improve the AIC values of the model. In conclusion, the feasibility study demonstrated that the current clinical protocol is suitable for the Phase 1 trial. The quantification of the limited blood sample volume on DBS was overcome by the reproducible extraction and sensitive LC-MS/MS assay method. In addition, the establishment of the PK co-models with Vincristine and M1 metabolite enables the derivation of conversion rate constant from VCR to M1 and elimination kinetics of Vincristine and M1 for individual subjects among the various types of tested cancers. Citation Format: Taylor Cornett, Lorita Agu, Lei Wu, Lu Dai, Jodi L. Skiles, Andrea R. Masters, Jamie L. Renbarger, Diana Shu-Lian Chow. Pharmacokinetic modeling of Vincristine and its metabolite in Kenyan pediatric cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 2801." @default.
• W4362543464 created "2023-04-06" @default.
• W4362543464 creator A5014367223 @default.
• W4362543464 creator A5022327161 @default.
• W4362543464 creator A5048025879 @default.
• W4362543464 creator A5055364883 @default.
• W4362543464 creator A5057351437 @default.
• W4362543464 creator A5072115451 @default.
• W4362543464 creator A5077444092 @default.
• W4362543464 creator A5087582944 @default.
• W4362543464 date "2023-04-04" @default.
• W4362543464 modified "2023-10-14" @default.
• W4362543464 title "Abstract 2801: Pharmacokinetic modeling of Vincristine and its metabolite in Kenyan pediatric cancer patients" @default.
• W4362543464 doi "https://doi.org/10.1158/1538-7445.am2023-2801" @default.
• W4362543464 hasPublicationYear "2023" @default.
• W4362543464 type Work @default.
• W4362543464 citedByCount "0" @default.
• W4362543464 crossrefType "journal-article" @default.
• W4362543464 hasAuthorship W4362543464A5014367223 @default.
• W4362543464 hasAuthorship W4362543464A5022327161 @default.
• W4362543464 hasAuthorship W4362543464A5048025879 @default.
• W4362543464 hasAuthorship W4362543464A5055364883 @default.
• W4362543464 hasAuthorship W4362543464A5057351437 @default.
• W4362543464 hasAuthorship W4362543464A5072115451 @default.
• W4362543464 hasAuthorship W4362543464A5077444092 @default.
• W4362543464 hasAuthorship W4362543464A5087582944 @default.
• W4362543464 hasConcept C112705442 @default.
• W4362543464 hasConcept C121608353 @default.
• W4362543464 hasConcept C126322002 @default.
• W4362543464 hasConcept C142724271 @default.
• W4362543464 hasConcept C143998085 @default.
• W4362543464 hasConcept C2776694085 @default.
• W4362543464 hasConcept C2776715637 @default.
• W4362543464 hasConcept C2776755627 @default.
• W4362543464 hasConcept C2777288759 @default.
• W4362543464 hasConcept C2777477808 @default.
• W4362543464 hasConcept C2778256501 @default.
• W4362543464 hasConcept C2779338263 @default.
• W4362543464 hasConcept C2779429289 @default.
• W4362543464 hasConcept C2780844630 @default.
• W4362543464 hasConcept C2993561819 @default.
• W4362543464 hasConcept C54355233 @default.
• W4362543464 hasConcept C71924100 @default.
• W4362543464 hasConcept C81885089 @default.
• W4362543464 hasConcept C86803240 @default.
• W4362543464 hasConcept C90924648 @default.
• W4362543464 hasConcept C98274493 @default.
• W4362543464 hasConceptScore W4362543464C112705442 @default.
• W4362543464 hasConceptScore W4362543464C121608353 @default.
• W4362543464 hasConceptScore W4362543464C126322002 @default.
• W4362543464 hasConceptScore W4362543464C142724271 @default.
• W4362543464 hasConceptScore W4362543464C143998085 @default.
• W4362543464 hasConceptScore W4362543464C2776694085 @default.
• W4362543464 hasConceptScore W4362543464C2776715637 @default.
• W4362543464 hasConceptScore W4362543464C2776755627 @default.
• W4362543464 hasConceptScore W4362543464C2777288759 @default.
• W4362543464 hasConceptScore W4362543464C2777477808 @default.
• W4362543464 hasConceptScore W4362543464C2778256501 @default.
• W4362543464 hasConceptScore W4362543464C2779338263 @default.
• W4362543464 hasConceptScore W4362543464C2779429289 @default.
• W4362543464 hasConceptScore W4362543464C2780844630 @default.
• W4362543464 hasConceptScore W4362543464C2993561819 @default.
• W4362543464 hasConceptScore W4362543464C54355233 @default.
• W4362543464 hasConceptScore W4362543464C71924100 @default.
• W4362543464 hasConceptScore W4362543464C81885089 @default.
• W4362543464 hasConceptScore W4362543464C86803240 @default.
• W4362543464 hasConceptScore W4362543464C90924648 @default.
• W4362543464 hasConceptScore W4362543464C98274493 @default.
• W4362543464 hasIssue "7_Supplement" @default.
• W4362543464 hasLocation W43625434641 @default.
• W4362543464 hasOpenAccess W4362543464 @default.
• W4362543464 hasPrimaryLocation W43625434641 @default.
• W4362543464 hasRelatedWork W1545612850 @default.
• W4362543464 hasRelatedWork W1571073982 @default.
• W4362543464 hasRelatedWork W1573985376 @default.
• W4362543464 hasRelatedWork W2018887623 @default.
• W4362543464 hasRelatedWork W2030363482 @default.
• W4362543464 hasRelatedWork W2056938528 @default.
• W4362543464 hasRelatedWork W2061279694 @default.
• W4362543464 hasRelatedWork W2063991714 @default.
• W4362543464 hasRelatedWork W2151580563 @default.
• W4362543464 hasRelatedWork W4362543464 @default.
• W4362543464 hasVolume "83" @default.
• W4362543464 isParatext "false" @default.
• W4362543464 isRetracted "false" @default.
• W4362543464 workType "article" @default.